here's a linkQuote:MindMed Co-Founder & Co-CEO JR Rahn said: "There is a growing trend in Western society to use Ayahuasca and DMT to facilitate a healing process for one's mind. However, there is very limited safety data and clinical trials evaluating DMT as a potential medicine so we are going to double down on understanding the therapeutic opportunity and more effective ways to administer DMT in a controlled setting to achieve this healing process."
Through this Phase 1 clinical trial, MindMed and the Liechti Lab are exploring how DMT can achieve experiential effects similar to Ayahuasca by testing a more controlled intravenous dosing method.
Does this seem like a very vague protocol with no clear hypothesis to anyone else? And if the intention is to replicate aya through an IV, who would an MAOI not be included? Possibly because all of the patents in MAOI pharmaceuticals have long expired and there is little to no profit potential in them, although it is arguably the major constituent of aya in favor of DMT?
Corporate health still sucks.
Sine experientia nihil sufficienter sciri potest -Roger Bacon
*γνῶθι σεαυτόν*